Ezra J. Margolin, MD, highlights a recent study examining antibiotic prescribing patterns for patients presenting to the emergency department with kidney stones. In the following video, Ezra J.
Surgeons at Cleveland Clinic completed the first commericial procedure using the Hugo robot-assisted surgery system in the US. The first US commercial surgical case using the Hugo robot-assisted ...
FDA approved Gozellix for prostate cancer imaging and expanded 177Lu-PSMA-617's label for mCRPC treatment. 64Cu-SAR-bisPSMA demonstrated efficacy in detecting recurrent prostate cancer in the COBRA ...
IsoPSA, a blood-based test, aids in diagnosing high-grade prostate cancer by analyzing PSA protein structural variants. FDA approval was based on a large-scale, prospective study and other validation ...
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial. On November 21, 2025, the FDA approved pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph ...
Krambeck pointed to the growing importance of medical management in stone disease prevention. In this video, Amy E. Krambeck, MD, a professor of urology at the Northwestern University Feinberg School ...
"As with all medications and services, it is important to check with the patient’s insurer to determine their policy and whether the medication will be covered," write Jonathan Rubenstein, MD, and ...
Metabolic health, especially HbA1c levels, significantly influences sexual function in aging men more than age alone. Increases in HbA1c correlate with declines in sperm motility and erectile function ...
The TOBY Test uses AI and gas chromatography–mass spectrometry to analyze urine for early cancer detection, offering a significant advantage over current methods. The FDA's breakthrough device ...
Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, antibiotic use, ...
Zoliflodacin, a first-in-class oral antibiotic, targets uncomplicated gonorrhea and has received FDA NDA acceptance and priority review status. Clinical trials ...
UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results